UK approves Nuvaxovid, the first protein-based COVID-19 vaccine

The UK has approved the first protein-based COVID-19 vaccine manufactured by Novavax.

The vaccine called Nuvaxovid (generic name NVX-CoV2373) is the fifth COVID-19 vaccine. approved According to the Medicines and Healthcare Products Regulatory Authority (MHRA), an independent UK drug regulator. Other COVID-19 vaccines approved for use in the UK include Pfizer / BioNTech, Modana, Johnson & Johnson, and Oxford / AstraZeneca vaccines.

Nuvaxovid is allowed for first and second doses in the United Kingdom for people over the age of 18.

“It’s great to see our world-renowned drug regulator approve another COVID-19 vaccine,” said Sajid Javid, UK Health and Social Welfare Secretary, in a statement.

“I want the UK to be the best place in the world to conduct clinical trials. This is a testament to the country’s leading R & D capabilities for vaccines. Tens of thousands of people here in the UK are in clinical trials. Participating in, contributing to valuable research showing that vaccines are safe and effective, “said Javid.

“The next step is for an independent joint committee on immunization and vaccination to consider using it as part of the UK’s COVID-19 vaccination program,” he said.

As a result of the meeting, the Commission will make recommendations on when and how to deploy the vaccine.

Novavax’s COVID-19 vaccine has recently received conditional approval from the European Commission. 9th COVID-19 vaccine It has been granted an emergency use list by the World Health Organization.

The protein-based double-dose vaccine was designed from the gene sequence of the first strain of SARS-CoV-2.

Munir Pirmohamed, chairman of the Human Medicine Committee, a committee of the MHRA, said the committee and its COVID-19 Expert Working Group “carefully reviewed the available evidence for safety, quality, and efficacy. He advised on the benefits risk. The vaccine balance is positive.

“Nuvaxovid uses recombinant protein-based technology that has been used for many years in the development of vaccines to prevent other diseases such as hepatitis B, so other COVIDs currently in use in the UK- It’s different from the 19 vaccine, “he said. “In reaching that decision, MHRA reviewed the results of two large clinical trials involving nearly 50,000 participants.”

Both trials were conducted before the emergence of the Omicron variant in November 2021. PREVENT-19 trial30,000 participants in the United States and Mexico. Another trial About 15,000 participants participated in the UK. Both exams were published in the New England Journal of Medicine.

“NVX-CoV2373 was created to generate antigens derived from the coronavirus spike (S) protein using Nuvaxovid’s recombinant nanoparticle technology, and is Nuvaxovid’s patented saponin-based Matrix-M ™ adjuvant. Antibodies that combine to enhance the immune response and stimulate high levels of neutralization, “a Maryland-based biotechnology company said earlier in a statement.

“NVX-CoV2373 contains a purified protein antigen and cannot replicate or cause COVID-19.”

June Raine, Chief Executive Officer of MHRA, has conducted independent batch tests on all UK-approved COVID-19 vaccines for quality control, including all COVID-19 vaccines in the UK. He said he is still monitoring the use of.

Mimi Nguyen Lee


Mimi Nguyen Ly is a reporter who covers world news with a focus on US news. She is based in Australia and has a background in clinical optometry. Contact Mimi at [email protected]